Itero and Biological E will collaborate to obtain worldwide approvals and commercialize jointly developed biopharmaceuticals. Itero will be responsible for financing the development of the drug candidates, while Biological E will be responsible for financing the manufacture of the products to meet worldwide demand.
Itero will retain commercial rights in the US, Europe, and Japan, while Biological E will retain commercial rights in all other territories.
Itero has also announced that it has secured a $21 million series A venture financing commitment. SV Life Sciences, the company’s largest shareholder, and Panorama Capital led the financing with additional participation from VenturEast. The proceeds will be used to fund the initial development of Itero’s therapeutic protein pipeline.